Identically, this study revealed that postoperative immunotherapy was one of the predictors to prolong the OS of ASTRI-NSCLC treated with DEB-BACE, which is per the additional immunotherapy that may improve the survival of advanced NSCLC after BAI/DEB-BACE, as reported (16). The gene discussed is BACE1; the disease is non-small cell lung carcinoma.